文献速递前列腺癌

平等医疗体系下非裔美国低危前列腺癌根治术后的结果:对主动监测的启示

African-American men with low-risk prostate cancer treated with radical prostatectomy in an equal-access health care system: implications for active surveillance.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-04-23

该观察性队列研究纳入美国退伍军人医疗系统2001至2015年间接受根治性前列腺切除术的2857例低危前列腺癌患者,比较非裔美国男性与白人男性的不良病理结局。中位随访7.1年,非裔美国男性升级至GG2的风险显著增加(RR=1.49,p<0.01),但升级至GG≥3、病理分期≥3、切缘阳性、PSA复发及全因死亡率均无显著差异。提示非裔美国男性在启动主动监测前可能需要额外评估如MRI引导活检。

要点

  • 在平等医疗体系中,非裔美国男性低危前列腺癌根治术后多数不良病理结局与白人男性无显著差异。
  • 非裔美国男性升级至Gleason分级分组2的风险显著高于白人男性(RR=1.49,p<0.01)。
  • 非裔美国男性启动主动监测前可能需要额外评估如MRI引导活检。

核心结论

  • 非裔美国男性与白人男性在升级至GG≥3、病理分期≥3、切缘阳性、PSA复发及全因死亡率方面无显著差异,但非裔美国男性升级至GG2的风险显著增加。

研究设计与样本

  • 观察性队列研究,纳入美国退伍军人事务部2001年1月1日至2015年10月31日期间诊断为低危前列腺癌(Gleason评分≤6、临床肿瘤分期≤2A、PSA≤10)并接受根治性前列腺切除术的患者,共2857例(非裔美国男性835例,白人男性2022例),中位随访7.1年。

主要发现

  • 非裔美国男性与白人男性相比,升级至GG≥3的RR=1.18(p=0.43),病理分期≥3的RR=0.95(p=0.74),切缘阳性的RR=1.14(p=0.20),PSA复发的SHR=1.26(p=0.06),全因死亡的SHR=1.26(p=0.16),均无统计学显著差异。
  • 非裔美国男性升级至GG2的风险显著高于白人男性(RR=1.49,p<0.01)。

关键数值与推荐

  • 低危前列腺癌定义为Gleason评分≤6、临床肿瘤分期≤2A、PSA≤10。
  • 非裔美国男性升级至GG2的RR=1.49(p<0.01),升级至GG≥3的RR=1.18(p=0.43)。

临床怎么用

  • 在平等医疗体系中,非裔美国男性低危前列腺癌患者多数不良病理结局与白人男性相似,但GG2升级风险更高,启动主动监测前可考虑额外评估如MRI引导活检。

局限性

  • 非裔美国男性GG2升级增加是否导致转移和前列腺癌特异性死亡等更差长期临床结局仍需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is concern that African-American men (AA) with low-risk prostate cancer may present with more aggressive disease and thus may not be candidates for active surveillance (AS). However, it is uncertain if poorer outcomes are due to disparities in access to medical care rather than true biological differences. METHODS: Observational cohort study of patients diagnosed with low-risk PC-Gleason score ≤6, clinical tumor stage ≤2A, and prostate specific antigen (PSA) level ≤10-at US Department of Veterans Affairs between January 1, 2001 and October 31, 2015 and treated with radical prostatectomy. Outcomes included upgrading to Gleason Grade Group 2 (GG2), GG ≥ 3, PSA recurrence, pathologic tumor stage ≥3, positive surgical margins, and all-cause mortality. RESULTS: A total of 2857 men (AA: 835 White: 2022) with a median follow-up of 7.1 years. Overall, there was no significant difference between AA and White men in upgrading to GG ≥ 3 (RR = 1.18, p = 0.43), tumor stage ≥3 (RR = 0.95, p = 0.74), positive surgical margins (RR = 1.14, p = 0.20), PSA recurrence (SHR = 1.26, p = 0.06), and all-cause mortality (SHR = 1.26, p = 0.16). However, there was a significant increase in upgrading for AA to GG2 (RR = 1.49, p < 0.01). CONCLUSIONS: There was no significant difference in most adverse pathologic outcomes between AA and White patients. However, GG2 upgrading was more common in AA men. The implication is that AA may need to undergo additional evaluation, such as a biopsy MRI, before initiating AS. Whether the increase in GG2 upgrading will lead to poorer long-term clinical outcomes such as metastasis and PCSM also requires further investigation.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Deka R, Parsons JK, Simpson DR, et al. African-American men with low-risk prostate cancer treated with radical prostatectomy in an equal-access health care system: implications for active surveillance. Prostate Cancer Prostatic Dis. 2020. PMID: 32327702. doi:10.1038/s41391-020-0230-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。